Interestingly, wild-type IDH2 is highly expressed in various cancers, including glioblastoma, lung, breast, esophageal, colorectal, and hepatocellular carcinomas and has been shown to promote tumor growth and therapy resistance [7,15,16,17,18,19,20,21]. Here, IDH2 is linked to neoplasm.